Clinical Trial Update: A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer [Phase 2]

View source ↗

Summary

A randomized, placebo-controlled Phase II trial assessed continuous maintenance therapy with BIBF 1120 (nintedanib) after chemotherapy in relapsed ovarian cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2014-12-04